Table 2. Comparison of clinical characteristics between NSCLCs harboring classic activating EGFR mutations and EGFR exon 18 mutations.
| Variables | Classic activating | Mutations in | p |
|---|---|---|---|
| mutations | exon 18 | ||
| (n = 661) | (n = 34) | ||
| Gender | |||
| Female | 420 (63.5%) | 27 (79.4%) | |
| Male | 241 (36.5%) | 7 (20.6%) | 0.067 |
| Age (y) | |||
| Mean | 60.0 | 60.9 | |
| SD | 10.0 | 11.5 | 0.652 |
| Smoking history | |||
| Ever | 140 (21.2%) | 4 (11.8%) | |
| Never | 521 (78.8%) | 30 (88.2%) | 0.276 |
| Tumor size (cm) | |||
| ≤3 | 518 (78.4%) | 23 (67.6%) | |
| >3 | 143 (21.6%) | 11 (32.4%) | 0.143 |
| Stage | |||
| I | 388 (58.7%) | 19 (55.9%) | |
| II–IV | 273 (41.3%) | 15 (44.1%) | 0.859 |
| Differentiation | |||
| Well/Moderate | 522 (79.0%) | 22 (64.7%) | |
| Poor | 139 (21.0%) | 12 (35.3%) | 0.056 |
Classic activating mutation: EGFR exon 19 deletions and L858R point mutation; SD: standard deviation.